U.S. markets close in 4 hours 9 minutes
  • S&P 500

    3,898.76
    +87.61 (+2.30%)
     
  • Dow 30

    31,589.58
    +657.21 (+2.12%)
     
  • Nasdaq

    13,531.28
    +338.93 (+2.57%)
     
  • Russell 2000

    2,263.92
    +62.87 (+2.86%)
     
  • Crude Oil

    61.55
    +0.05 (+0.08%)
     
  • Gold

    1,733.30
    +4.50 (+0.26%)
     
  • Silver

    26.95
    +0.51 (+1.93%)
     
  • EUR/USD

    1.2057
    -0.0031 (-0.25%)
     
  • 10-Yr Bond

    1.4410
    -0.0190 (-1.30%)
     
  • GBP/USD

    1.3941
    +0.0019 (+0.13%)
     
  • USD/JPY

    106.6500
    +0.1480 (+0.14%)
     
  • BTC-USD

    48,772.29
    +5,261.99 (+12.09%)
     
  • CMC Crypto 200

    976.31
    +48.07 (+5.18%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Estimating The Intrinsic Value Of Amgen Inc. (NASDAQ:AMGN)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Today we will run through one way of estimating the intrinsic value of Amgen Inc. (NASDAQ:AMGN) by taking the expected future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. Believe it or not, it's not too difficult to follow, as you'll see from our example!

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

See our latest analysis for Amgen

Step by step through the calculation

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) forecast

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

US$10.3b

US$10.2b

US$11.1b

US$11.4b

US$11.6b

US$11.9b

US$12.1b

US$12.4b

US$12.7b

US$13.0b

Growth Rate Estimate Source

Analyst x4

Analyst x4

Analyst x2

Analyst x2

Est @ 2.19%

Est @ 2.2%

Est @ 2.2%

Est @ 2.21%

Est @ 2.21%

Est @ 2.21%

Present Value ($, Millions) Discounted @ 8.9%

US$9.5k

US$8.6k

US$8.6k

US$8.1k

US$7.6k

US$7.1k

US$6.7k

US$6.2k

US$5.9k

US$5.5k

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$74b

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.2%. We discount the terminal cash flows to today's value at a cost of equity of 8.9%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$13b× (1 + 2.2%) ÷ (8.9%– 2.2%) = US$197b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$197b÷ ( 1 + 8.9%)10= US$84b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$157b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of US$229, the company appears about fair value at a 15% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

dcf
dcf

Important assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Amgen as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.9%, which is based on a levered beta of 1.119. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Amgen, we've compiled three further elements you should explore:

  1. Risks: As an example, we've found 2 warning signs for Amgen that you need to consider before investing here.

  2. Future Earnings: How does AMGN's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQGS every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.